News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
December, 2023
December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Sebastian Schmidt: Yesterday, one of my highlights at the WCLC23 was the presentation of Jens Vogel-Claussen about the interim results of the HANSE study.
Photo from Sebastian Schmidt/LinkedIn
Sep 12, 2023, 19:16

Sebastian Schmidt: Yesterday, one of my highlights at the WCLC23 was the presentation of Jens Vogel-Claussen about the interim results of the HANSE study.

Quoting Sebastian Schmidt, Head of Strategy, Innovation, and Medical Affairs in the Computed Tomography Business Line at Siemens Healthineers, on LinkedIn:

”Lung Cancer Screening: First results from the HANSE study. Yesterday, one of my highlights at the WCLC23 was the presentation of Jens Vogel-Claussen about the interim results of the HANSE study.

Main takeaways:

– First round of CT screening successfully completed (>5000 scans). Great.
– >60 cancers detected, above expectations (>1.5% 5-years incidence)
– About two thirds of detected cancers in early stage (I/II). Good result, remember that the results in later (incidence) rounds are better than in the first (prevalence) round, where you see a lot of pre-existing late-stage cancers. Same order of magnitude as the large trials (NELSON etc).
– Self-assessment of participants correlated almost perfectly with physician’s assessment (~1% deviation) – shows that self-assessment is a valid tool for risk detemination
– The PLCO2012 risk model performs better than the NELSON risk model. Not surprising, it includes 10 years more of experience.

This another successful lung screening program, and especially important that it shows feasibility of lung cancer screening within the German healthcare system.

The results on PLCO vs NELSON may encourage the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection to rethink their aim to define fix criteria in a statutory order (Rechtsverordnung) – we see continuous improvement of risk models, and fixing them for a long time would exclude Germany from such progress in science. At least there should be a review period of around five years to include improvements.”

Source: Sebastian Schmidt/LinkedIn

 

cancer cancer screening Germany Jens Vogel-Claussen Nature Conservation Nuclear Safety and Consumer Protection OncoDaily Oncology Sebastian Schmidt WCLC23
Insight
Dec 9, 2023, 04:44
President Biden: It's good for the millions of Americans who can't afford their medications
Blog
Dec 9, 2023, 00:38
Thomas Hofmarcher: This is what a great panel discussion looks like!
Blog
Dec 9, 2023, 00:32
Zhiheng Xu: It's not just about how much statistics you know
Blog
Dec 9, 2023, 00:23
Priscilla Chan: Mark and I wrote our annual letter this year about how some of our earliest bets in science are letting us take advantage of this moment in AI
Blog
Dec 9, 2023, 00:18
David Fajgenbaum: 1 in 10 of us will develop a disease with no treatments
Career
Dec 8, 2023, 17:54
Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award
Drugs
Dec 8, 2023, 17:50
Pure Biologics to test molecule PBA-0405 in project PB004 in a Phase 0 clinical trial in patients with solid tumors - The Antibody Society
Drugs
Dec 8, 2023, 17:46
Earle Burgess: Interested in new treatments being developed for advanced (urothelial) bladder cancer?
Insight
Dec 8, 2023, 17:40
Ibrahim Halil Sahin: A common question I received after my tweet on the PEGASUS trial...
Career
Dec 8, 2023, 17:35
Timothy M. Pawlik: Excited to announce Samilia Obeng-Gyasi as THE inaugural Endowed Surgical Professor in Health Equity
Insight
Dec 8, 2023, 17:32
Daniel Stover: Tumor genomic testing (TGT) is standard for MBC patients
Blog
Dec 8, 2023, 17:27
Tedros Adhanom Ghebreyesus: Gaza cannot afford to lose any more hospitals…
Insight
Positive
Societies
Career